Search Results - Bentsion, D.

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    EP-1431: SBRT for patients with spine metastases using LINAC

    EP-1431: SBRT for patients with spine metastases using LINAC by Mironova, Y, Bentsion, D, Bayankin, S

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% — 3-year update

    10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with progr... by Kilickap, S., Özgüroğlu, M., Sezer, A., Gumus, M., Bondarenko, I., Gogishvili, M., Türk, H.M., Cicin, I., Bentsion, D., Gladkov, O.A., Clingan, P., Sriuranpong, V., He, X., Pouliot, J-F., Seebach, F., Lowy, I., Gullo, G., Rietschel, P.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

    FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1 by Bondarenko, I., Sezer, A., Kilickap, S., Gümüş, M., Özgüroğlu, M., Gogishvili, M., Turk, H.M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Mcginniss, J., Pouliot, J., Lee, S., Seebach, F., Lowy, I., Gullo, G., Rietschel, P.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

    OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC by Kilickap, S., Sezer, A., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H.M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Li, S., Lee, S., Makharadze, T., Paydas, S., Nechaeva, M., Seebach, F., Weinreich, D.M., Yancopoulos, G.D., Gullo, G., Lowy, I., Rietschel, P.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50

    P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50 by Sezer, A., Gogishvili, M., Bentsion, D., Kilickap, S., Lowczak, A., Gumus, M., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Lee, S., Li, S., Snodgrass, P., Navarro, M., Lowy, I., Rietschel, P.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

    Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlle... by Sezer, Ahmet, Kilickap, Saadettin, Gümüş, Mahmut, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M, Cicin, Irfan, Bentsion, Dmitry, Gladkov, Oleg, Clingan, Philip, Sriuranpong, Virote, Rizvi, Naiyer, Gao, Bo, Li, Siyu, Lee, Sue, McGuire, Kristina, Chen, Chieh-I, Makharadze, Tamta, Paydas, Semra, Nechaeva, Marina, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Gullo, Giuseppe, Lowy, Israel, Rietschel, Petra

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: